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Objectives We examined compliance with performance measures for 14,464 patients enrolled from July 2008 through
June 2009 into the American College of Cardiology’s PINNACLE (Practice Innovation And Clinical Excellence)
program to provide initial insights into the quality of outpatient cardiac care.
Background Little is known about the quality of care of outpatients with coronary artery disease (CAD), heart failure, and
atrial fibrillation, and whether sex and racial disparities exist in the treatment of outpatients.
Methods The PINNACLE program is the first, national, prospective office-based quality improvement program of cardiac
patients designed, in part, to capture, report, and improve outpatient performance measure compliance. We ex-
amined the proportion of patients whose care was compliant with established American College of Cardiology,
American Heart Association, and American Medical Association-Physician Consortium for Performance Improve-
ment (ACC/AHA/PCPI) performance measures for CAD, heart failure, and atrial fibrillation.
Results There were 14,464 unique patients enrolled from 27 U.S. practices, accounting for 18,021 clinical visits. Of
these, 8,132 (56.4%) had CAD, 5,012 (34.7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibril-
lation. Data from the PINNACLE program were feasibly collected for 24 of 25 ACC/AHA/PCPI performance mea-
sures. Compliance with performance measures ranged from being very low (e.g., 13.3% of CAD patients
screened for diabetes mellitus) to very high (e.g., 96.7% of heart failure patients with blood pressure assess-
ments), with moderate (70% to 90%) compliance observed for most performance measures. For 3 performance
measures, there were small differences in compliance rates by race or sex.
Conclusions For more than 14,000 patients enrolled from 27 practices in the outpatient PINNACLE program, we found that
compliance with performance measures was variable, even after accounting for exclusion criteria, suggesting an
important opportunity to improve the quality of outpatient care. (J Am Coll Cardiol 2010;56:8–14) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.043m
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uidelines that improve patient outcomes and for which data
an be feasibly collected and acted upon (1,2). While perfor-
ance measures have been created for both the inpatient
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June 29, 2010:8–14 Cardiac Performance Measures in Outpatientset With The Guidelines, have demonstrated improvements
ver time in performance measure compliance at hospital
ischarge (6–9). To date, however, there have been no sys-
ematic efforts to prospectively assess compliance with Amer-
can College of Cardiology (ACC), American Heart Associa-
ion (AHA), and American Medical Association-Physician
onsortium for Performance Improvement (PCPI) perfor-
ance measures among outpatients. Given that the majority of
ardiac patients are treated as outpatients, there is a compelling
eed to systematically measure the quality of care, as quantified
y established performance measures, among outpatients so
hat potential gaps in the quality of outpatient care can be
dentified and addressed as targets for quality improvement.
See page 15
Accordingly, we examined baseline compliance rates to
erformance measures among outpatients with coronary
rtery disease (CAD), heart failure, and atrial fibrillation in
he ACC’s PINNACLE (Practice Innovation And Clinical
xcellence) program. The PINNACLE program, a pro-
pective registry of outpatient care, represents an ideal data
ource to examine this question because it systematically
aptures outpatient compliance to each performance mea-
ure for these 3 cardiac conditions.
ethods
he PINNACLE program and study population. In
008, the ACC launched the PINNACLE program (for-
erly known as the Improving Continuous Cardiac Care,
r IC3)—the first, national, prospective, office-based, car-
iac quality improvement registry in the U.S. Academic and
rivate practices were invited to participate in the PINNACLE
rogram through the ACC’s website, e-mails, brochures,
nd information webinars. Physicians or practice represen-
atives (e.g., administrators) in interested practices under-
ent a series of educational training sessions before data
ubmission. Within participating practices, a variety of
ongitudinal patient data were collected at the point of care,
ncluding patients’ symptoms, vital signs, medications, and
ecent hospitalizations (Online Appendix). In addition, data
or each ACC/AHA/PCPI performance measure for CAD
3), heart failure (4), and nonvalvular atrial fibrillation (5)
ere collected. Data collection was achieved through 1 of 2
echanisms at the practice level: 1) paper forms; or
) modification of a practice’s electronic medical record data
ollection system to comprehensively capture the additional
equisite data elements for PINNACLE program partici-
ation. Data from practices were routinely submitted to the
CC’s NCDR. Data quality checks and analysis were
ubsequently performed at the St. Luke’s Mid America
eart Institute (Kansas City, Missouri), the primary ana-
ytical center for the PINNACLE program.
For the purposes of this study, we assessed clinical data fromatients enrolled into the PINNACLE program from July 1, c008, through June 30, 2009. For
any of the cardiac performance
easures, rates are reported at the
atient level; therefore, we in-
luded data from only the baseline
nrollment visit to minimize over-
epresentation by patients with
ultiple visits. For several perfor-
ance measures for which data are
eported at the visit level, we in-
luded data from all visits during
he study period. The final study
ample comprised 14,464 patients
nrolled from 27 practices encom-
assing 18,021 clinical visits.
tudy outcomes. The primary
utcome was compliance with
ach of the ACC/AHA/PCPI
erformance measures for CAD
n  11), heart failure (n  11),
nd atrial fibrillation (n 3). Compliance was defined as the
umber of patients (or visits) that met the performance
easure divided by the number of eligible patients (or visits)
or that performance measure. Patients were considered eligi-
le if they met the established inclusion criteria for that
erformance measure and did not have a medical (e.g., beta-
locker use after myocardial infarction in a patient with
ypotension or bradycardia) or personal (e.g., patient refusal
o take warfarin for atrial fibrillation) contraindication for
hat measure. Because eligibility requirements differed
cross measures, a patient could be excluded from analyses
or some performance measures but included in others.
hus, within these ideal subsets of patients, optimal perfor-
ance was a rate of 100%. As secondary outcomes, we also
xamined whether compliance rates for select performance
easures differed by race, sex, or age (75 years vs. 75
ears).
tatistical analyses. Summary statistics for patients’ demo-
raphic and clinical characteristics were reported as means
ith standard deviations for continuous variables and as
roportions for categorical variables. Compliance rates for
ach of the ACC/AHA/PCPI performance measures were
hen determined using aggregate proportions. The numer-
tor for these rates was the total number of patients (or
isits) that met the performance measure and the denomi-
ator was the total number of eligible patients (or visits) for
hat performance measure.
A priori secondary analyses examined whether compli-
nce rates for 7 select performance measures differed by
atients’ race or sex. For the race analysis, we limited the
tudy sample to those patients who identified themselves as
f either black or white race (n  12,261). The select
erformance measures examined included use of beta-
lockers after myocardial infarction, lipid-lowering drug
nd antiplatelet therapy in patients with CAD, angiotensin-
Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACE-I  angiotensin-
converting enzyme inhibitor
AHA  American Heart
Association
ARB  angiotensin-
receptor blocker
CAD  coronary artery
disease
CI  confidence interval
DM  diabetes mellitus
PCPI  American Medical
Asssociation-Physician
Consortium for
Performance Improvement
RR  relative rateonverting enzyme inhibitor (ACE-I) or angiotensin-
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Cardiac Performance Measures in Outpatients June 29, 2010:8–14eceptor blocker (ARB) therapy for patients with CAD and
ither left ventricular systolic dysfunction (ejection fraction
40%) or diabetes mellitus (DM), beta-blocker and ACE-I
r ARB therapy for patients with heart failure and left
entricular systolic dysfunction, and warfarin in patients
ith atrial fibrillation and a CHADS2 score of2 (10). The
HADS2 score is a clinical prediction rule for estimating
he risk of stroke in patients with atrial fibrillation, with 1
oint each assigned for coexisting congestive heart failure,
ypertension, age 75 years, and diabetes mellitus, and 2
oints assigned for prior transient ischemic attack or stroke.
To accomplish these secondary analyses, separate 2-level
ierarchical models were constructed for the race and sex
nalyses (11). In these models, the clinic site and the
roportion of patients who were black or female at each
linic were evaluated as random effects, and their estimates
epresent within-clinic differences by race or sex, fully
djusting for all observable and unobservable between-clinic
ifferences. Because compliance rates exceeded 10%, we
tilized log-binomial or modified Poisson regression models
t all steps, which estimate a relative rate (RR) directly (as
pposed to an odds ratio obtained from logistic regression,
hich may overestimate racial or sex differences) (12,13).
inally, we also examined whether warfarin use in patients
ith atrial fibrillation and a CHADS2 score of 2 differed
y age (75 years vs. 75 years), using similarly con-
tructed hierarchical models.
For each analysis, the null hypothesis was evaluated at a
-sided significance level of 0.05 with 95% confidence
ntervals (CIs) calculated. All analyses were performed
ith SAS version 9.2 (SAS Institute, Cary, North Caro-
ina) and R version 2.7.0 (Foundation for Statistical
omputing, Vienna, Austria) (14).
esults
f the 27 practices, all were cardiology subspecialty prac-
ices, 25 (92.3%) were private practices, and 11 (40.7%)
ere university affiliated. Seventeen (63.0%) practices were
ocated in urban centers, one-half (14 [51.9%]) had 10 or
ore physician providers, and two-thirds (18 [66.7%])
mployed nurse-practitioners or physician-assistants.
Baseline characteristics of the study population of 14,464
atients are presented in Table 1. The median number of
atients enrolled from each practice was 354 (interquartile
ange 89 to 549 patients). The mean age of the study
opulation was 67.2  13.9 years, 2,234 (17.7%) patients
ith data on race were black, and 6,743 (46.6%) were
omen. More than one-half of enrolled patients had CAD,
in 3 patients had heart failure, and nearly 1 in 5 patients
ad atrial fibrillation. One-half (7,296 [50.4%]) of the study
ohort had at least 2 of these 3 cardiac conditions, and 712
4.9%) had all 3 conditions.
Within the study sample, the mean body mass index was
1.0 8.0 kg/m2, mean systolic blood pressure was 127.4
8.6 mm Hg, and mean diastolic blood pressure was 74.2  D1.4 mm Hg. More than one-half of the study cohort had
revalent hypertension or dyslipidemia, nearly one-half
ere current or former smokers, 1 in 5 patients had diabetes
ellitus, slightly more than 10% had stable angina or a prior
yocardial infarction, and a small percentage of patients
ad peripheral arterial disease, prior stroke, or recent coro-
ary revascularization.
ompliance with CAD performance measures. Table 2
ummarizes rates of compliance with 11 performance mea-
ures among the 8,132 patients identified with CAD. Rates
anged from being very high for blood pressure assessment
94.0% [7,235 of 7,698]) to very poor for cardiac rehabili-
ation referral after myocardial infarction or coronary artery
ypass surgery (18.1% [200 of 1,108]) and screening for
aseline Characteristics ofhe Study S mple (n  14,464)Table 1 B s line Characteristics ofthe Study Sample (n  14,464)
Age, yrs 67.2 13.9
Sex
Male 53.4%
Female 46.6%
Race*
White 79.4%
Black 17.7%
Other 2.9%
Cardiac conditions with performance measures
Coronary artery disease 56.2%
Heart failure 34.7%
With LVEF 40% 21.5%
Atrial fibrillation 19.3%
With CHADS2 score 2 59.0%
Vitals
Body mass index, kg/m2 31.0 8.0
Systolic blood pressure, mm Hg 127.4 18.6
Diastolic blood pressure, mm Hg 74.2 11.4
Medical history
Tobacco use
Current 10.6%
Former 36.5%
Never 52.8%
Hypertension 69.5%
Dyslipidemia 52.4%
Diabetes mellitus 19.4%
Stable angina 11.2%
Unstable angina 0.6%
Prior myocardial infarction 12.1%
Peripheral arterial disease 5.8%
Prior stroke 3.1%
Cardiac events in past 12 months
Myocardial infarction 2.0%
Percutaneous coronary intervention 3.6%
Coronary artery bypass graft 2.7%
Valve surgery 0.5%
Heart transplant 0.0%
alues are mean  SD or %. *Among the 12,624 patients with data on race.
CHADS2  stroke risk score for atrial fibrillation, comprised of: congestive heart failure,
ypertension, age 75 years, diabetes mellitus, and prior stroke or transient ischemic attack;
VEF  left ventricular ejection fraction.M (13.3% [822 of 6,199]). Adherence to beta-blocker
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June 29, 2010:8–14 Cardiac Performance Measures in Outpatientsherapy after myocardial infarction (86.4% [1,540 of
,782]), ACE-I/ARB therapy in patients with concurrent
eft ventricular systolic dysfunction or DM (72.4% [3,349 of
,623]), use of antiplatelet therapy (84.9% [6,742 of 7,944]),
nd annual lipid profile assessment (74.3% [6,044 of 8,132])
ell between these extremes. In addition, we were able to
etermine that use of thienopyridine therapy within 12 months of
drug-eluting stent—a Class I recommendation—was 81.9%
325 of 397).
ompliance with heart failure performance measures.
able 3 summarizes rates of compliance with 11 perfor-
ance measures among the 5,012 patients identified with
ny heart failure, of whom 1,076 (21.5%) had left ventric-
lar systolic dysfunction. Similar to the CAD performance
easures, compliance rates for heart failure performance
easures ranged from being very high for blood pressure
96.7% [6,251 of 6,462 encounters]) and weight (96.0%
6,149 of 6,402 encounters]) assessment and for beta-
locker therapy in patients with left ventricular systolic
Compliance Rates for Coronary Artery DiseasePerformance Measures in 8,132 PatientsTable 2 Compliance Rates fo Coronary ArtePerformance Measures in 8,132 Pa
Performance Measure Unit of A
Beta-blocker therapy after myocardial infarction Patie
Blood pressure measurement Last
Antiplatelet therapy Patie
Screening for diabetes mellitus Patie
Smoking query Patie
Smoking cessation Patie
Symptom and activity assessment Patie
ACE-I or ARB therapy Patie
Annual lipid profile Patie
Drug therapy for lowering LDL cholesterol Patie
Cardiac rehabilitation referral† Patie
For each of the 11 coronary artery disease performancemeasures, rate
number of patients (or visits) that met the performance measure, and
visits) for that performance measure. Patients were excluded if me
assessed at either the patient or encounter level. †Applicable to patien
cardiac transplant.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotens
Compliance Rates for Heart Failure PerformanceTable 3 Compliance Rates for Heart Failure
Performance Measure Unit o
Left ventricular systolic function assessment
ACE-I or ARB therapy for patients with LVEF40%
Beta-blocker therapy for patients with LVEF40%
Weight measurement
Blood pressure measurement
Patient education on heart failure
Assessment of activity level
Assessment of clinical signs of volume overload
Assessment of clinical symptoms of volume overload
Initial laboratory tests on new heart failure diagnoses
Warfarin therapy for patients with atrial fibrillation
For each of the 11 heart failure performance measures, rates of comp
of patients (or visits) that met the performance measure, and the den
for that performance measure. Patients were excluded if medical or p
either the patient or encounter level.
LVEF  left ventricular ejection fraction; other abbreviations as in Table 2.ysfunction (93.1% [981 of 1,054]), to very poor for heart
ailure patient education (43.8% [2,194 of 5,012]) and
ssessment of heart failure clinical signs on examination
23.7% [1,533 of 6,462]). Compliance with ACE-I/ARB in
atients with left ventricular systolic dysfunction (85.8%
879 of 1,025]), warfarin for patients with concurrent atrial
brillation (80.6% [859 of 1,066]), and clinical symptom
ssessment (88.9% [5,742 of 6,462]) fell between these
xtremes.
ompliance with atrial fibrillation performance measures.
ates of compliance for 2 of 3 performance measures
or atrial fibrillation could be reliably assessed in
INNACLE. Assessment of thromboembolic risk was
erformed in 1987 (73.6%) patients with nonvalvular atrial
brillation, and this rate did not differ among those 75
ears of age (72.0%) or 75 years of age (75.1%) (adjusted
R: 1.00; 95% CI: 0.97 to 1.04; p  0.84). Nearly 3 in 5
atients with nonvalvular atrial fibrillation had a CHADS2
core of 2 (n  1,643 [59.0%]). Warfarin was appropri-
isease
s
ment* Denominator Numerator Compliance Rate
1,782 1,540 86.4%
nter 7,698 7,235 94.0%
7,944 6,742 84.9%
6,199 822 13.3%
8,132 6,812 83.8%
500 356 71.2%
8,132 6,981 85.8%
4,623 3,349 72.4%
8,132 6,044 74.3%
1,607 1,355 84.3%
1,108 200 18.1%
pliance were determined. The numerator for these rates was the total
ominator for these rates was the total number of eligible patients (or
r personal reasons were cited by their physicians. *Measures were
ecent myocardial infarction, coronary artery bypass graft surgery, and
tor blocker; LDL  low-density lipoprotein.
sures in 5,012 Patientsrmance Measures in 5,012 Patients
ssment* Denominator Numerator Compliance Rate
s 5,012 4,181 83.4%
s 1,025 879 85.8%
s 1,054 981 93.1%
ters 6,402 6,149 96.0%
ters 6,462 6,251 96.7%
s 5,012 2,194 43.8%
ters 6,462 5,628 87.1%
ters 6,462 1,533 23.7%
ters 6,462 5,742 88.9%
s 180 27 15.0%
s 1,066 859 80.6%
ere determined. The numerator for these rates was the total number
or for these rates was the total number of eligible patients (or visits)
reasons were cited by their physicians. *Measures were assessed atry D
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Cardiac Performance Measures in Outpatients June 29, 2010:8–14tely used for stroke prophylaxis in nearly 4 in 5 of these
atients (1,302 of 1,643 [79.2%]), and this rate did not
iffer among those 75 years of age (444 of 549 [80.9%])
nd 75 years of age (858 of 1,094 [78.4%]) (adjusted RR:
.96; 95% CI: 0.92 to 1.01; p  0.15). Finally, among
atients taking warfarin, we were unable to adequately
ssess patients’ compliance with monthly monitoring of
nticoagulation levels.
ubgroup analyses. In secondary analyses for select per-
ormance measures, we found that compliance rates were
imilar between black and white patients for all 4 CAD
erformance measures and for warfarin use in patients with
trial fibrillation and a CHADS2 score of2 (Table 4). For
eart failure performance measures among patients with left
entricular systolic dysfunction, compliance rates were sim-
lar between black and white patients for beta-blocker use,
ut blacks were less likely to receive ACE-I/ARB therapy
84.8% vs. 85.3%; adjusted RR: 0.93 [95% CI: 0.86 to 1.00];
 0.05), although these differences were numerically
mall.
We also found that compliance rates were generally
imilar between men and women for these select perfor-
ance measures, although small numerical differences by
ex were observed for warfarin use among patients with
trial fibrillation and a CHADS2 score of 2 (80.7% for
en vs. 75.7% for women; adjusted RR: 0.94 [0.89 to 0.99];
 0.03) and for ACE-I/ARB therapy in eligible CAD
atients (72.1% for men vs. 71.7% for women; adjusted RR:
.96 [95% CI: 0.92 to 1.00]; p  0.05) (Table 5).
Racial Differences in Rates of Compliance for STable 4 Racial Differences in Rates of Comp
Performance Measure
Wh
(n  1
CAD: beta-blocker after myocardial infarction 86
CAD: antiplatelet therapy 84
CAD: ACE-I or ARB in patients with LVEF 40% 72
CAD: antilipid therapy 84
HF: beta-blocker in patients with LVEF 40% 92
HF: ACE-I or ARB in patients with LVEF 40% 84
AF: warfarin in patients with CHADS2 score 2 79
Compliance rates by patients’ race are shown for 7 coronary artery dis
analysis was restricted to those patients of white or black race only. R
AF  atrial fibrillation; CI  confidence interval; HF  heart failure;
Sex Differences in Rates of Compliance for SeleTable 5 Sex Differences in Rates of Complia
Performance Measure
M
(n 
CAD: beta-blocker after myocardial infarction 86
CAD: antiplatelet therapy 84
CAD: ACE-I or ARB in patients with LVEF 40% 72
CAD: antilipid therapy 85
HF: beta-blocker in patients with LVEF 40% 92
HF: ACE-I or ARB in patients with LVEF 40% 84
AF: warfarin in patients with CHADS2 score 2 80
Compliance rates by patients’ sex are shown for 7 coronary artery disea
rates are adjusted for clinic site, physician, and patient’s age and race.
Abbreviations as in Tables 2, 3, and 4.iscussion
n this study, we examined compliance rates with perfor-
ance measures among the first 14,000-plus outpatients
nrolled into the PINNACLE program—the first, na-
ional, outpatient, cardiac quality improvement registry
n the U.S. There were several key findings. First, we
ound that all but 1 of the 25 performance measures for
AD, heart failure, and atrial fibrillation could be feasi-
ly measured in the PINNACLE program, demonstrat-
ng the feasibility of prospective performance measure-
ent monitoring. Second, there was wide variation in
ompliance rates for CAD and heart failure performance
easures and only moderate compliance for atrial fibril-
ation performance measures, suggesting current gaps in
he quality of outpatient care. However, while rates were
uboptimal for a number of performance measures, these
esults identify opportunities for future improvement and
rovide a valuable benchmark with which progress can be
easured. Third, although racial and sex differences have
een reported for a variety of medical procedures and
reatments, there were no substantial racial or sex differ-
nces in compliance rates for key performance measures
or these 3 cardiac conditions. Collectively, this is the
rst comprehensive report of cardiac performance mea-
ure compliance among outpatients in the U.S., and our
ndings provide important insights into the quality of
are of outpatients with CAD, heart failure, and atrial
brillation.
Performance Measurese for Select Performance Measures
)
Blacks
(n  2,234)
Adjusted RR
(95% CI) p Value
89.5% 1.03 (0.96–1.10) 0.21
89.1% 1.01 (0.98–1.04) 0.73
79.3% 1.01 (0.96–1.07) 0.64
84.0% 0.98 (0.92–1.05) 0.60
92.6% 0.98 (0.93–1.02) 0.34
85.3% 0.93 (0.86–1.00) 0.05
79.2% 1.01 (0.91–1.12) 0.90
AD), heart failure, and atrial fibrillation performance measures. This
ates are adjusted for clinic site, physician, and patient’s age and sex.
relative rate; other abbreviations as in Tables 2 and 3.
rformance Measuresfor Select Performance Measures
)
Women
(n  6,743)
Adjusted RR
(95% CI) p Value
85.6% 0.98 (0.94–1.02) 0.37
83.2% 0.98 (0.96–1.00) 0.08
71.7% 0.96 (0.92–1.00) 0.05
81.5% 0.96 (0.91–1.01) 0.11
91.9% 0.99 (0.95–1.03) 0.64
86.7% 1.03 (0.97–1.10) 0.32
75.7% 0.94 (0.89–0.99) 0.03
), heart failure, and atrial fibrillation performance measures. Relativeelectlianc
ites
0,027
.0%
.5%
.5%
.8%
.5%
.8%
.3%
ease (Cct Pence
en
7,671
.4%
.4%
.1%
.6%
.4%
.1%
.7%
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June 29, 2010:8–14 Cardiac Performance Measures in OutpatientsOur study findings extend the work of others who have
reviously examined compliance with cardiac performance
easures for hospitalized patients. Studies within quality
mprovement registries, such as the NCDR and Get With
he Guidelines, have previously found baseline gaps in the
uality of inpatient cardiac care and improvements in
ompliance rates over time (6 –9). However, determining
ompliance rates with key quality indicators among
utpatients—who represent the large majority of patients
ith CAD, heart failure, and atrial fibrillation—has until
ecently remained elusive because of the unique challenges
f collecting data on performance measures in outpatient
linics. This is because data on performance measures
uring an outpatient clinical encounter need to be prospec-
ively captured at the “point of care” to ensure the accuracy
nd completeness of the requisite clinical data from which
erformance measures can be quantified. In contrast, data
or inpatient registries can often be retrospectively ab-
tracted. In this study, we were able to demonstrate that the
INNACLE program was successful in measuring compli-
nce for 24 of 25 performance measures for 3 common
ardiac conditions, thereby laying the foundation for future
tudies of outpatient compliance with cardiac performance
easures and the potential use of the PINNACLE data for
ublic reporting.
We found substantial variation in compliance rates for
ardiac performance (from 13% to 97%), even after allowing
ractices to exclude patients for medical (e.g., contraindica-
ions, allergies) or personal (e.g., patient refusal, cost of
edication) reasons for each measure. This suggests signif-
cant opportunities to elevate the quality of outpatient care,
n area of growing national concern given the high 30-day
eadmission rates for both heart failure and coronary artery
isease (15). Moving forward, the critical challenge for the
INNACLE program will be to define the mechanisms
hrough which compliance rates for performance mea-
ures can be improved. That could occur through its
nformative quarterly reports with detailed benchmarking
o other PINNACLE practices. However, there is a lag
ime with such reports, and they do not ensure that
hysicians in busy practices will be able to improve future
ompliance. Future development of real-time decision
upport during the clinical encounter may facilitate
igher compliance rates and should be investigated as a
eans for improving care (16). Future PINNACLE studies
ill need to examine trends in performance measure com-
liance, the association of increased compliance rates with
isease-specific outcomes (e.g., readmission rates), and the
haracteristics of practices with the greatest level of perfor-
ance and improvement.
In general, busy clinical practices have been unwilling or
nable to devote significant time and personnel resources for
rospective outpatient data collection. The PINNACLE
rogram has addressed these resource concerns in its design
nd implementation by: 1) allowing for data typically
ollected by a practice’s electronic medical record system to cutopopulate the PINNACLE data collection system so as
o minimize redundant data entry; and 2) by providing an
conomic incentive (additional Medicare payments) for
ractices through improved reporting of performance for
he Physician Quality Reporting Initiative (PQRI). The
conomic incentive arises because clinical practices would
o longer have to expend time and resources to retrospec-
ively collect the same data for performance measure and
QRI reporting at the end of the year, when the data would
ave little utility for quality improvement. If participation in
he PINNACLE program further improves performance
easure and PQRI compliance, this would provide an
dditional economic incentive for practices to participate.
Our study findings should be interpreted in light of the
ollowing limitations. This first report of the PINNACLE
rogram involved more than 14,000 patients from 27 highly
otivated practices. Therefore, compliance rates for cardiac
erformance measures in other U.S. practices may actually
e lower than that reported in this study. Second, while
ractices were asked to submit data on all their cardiac
atients, the PINNACLE program has no way of deter-
ining whether data on some cardiac patients were ex-
luded from the program. However, to the extent that
articipating practices depend upon the PINNACLE pro-
ram to report for their pay-for-performance and PQRI
easures, it is in the practices’ economic interests to submit
omplete data on all their cardiac patients. Third, because
he PINNACLE program allows clinicians to designate
edical and patient exclusions for each performance mea-
ure, it is possible that practices may “game” the system by
ssigning exclusions for patients who are otherwise not
ompliant with a particular performance measure. Despite
his possibility, we still found substantial gaps in compliance
or a number of performance measures. Fourth, it is possible
hat low compliance rates with certain performance mea-
ures reflected underdocumentation rather than underper-
ormance. And finally, while compliance with performance
easures is viewed as a metric of quality care, this current
tudy was not designed to examine specific clinical out-
omes. Adequately powered studies are therefore needed to
xamine the association of outpatient performance measure
ompliance and improvements in compliance over time with
utcomes such as readmission and mortality.
onclusions
ompliance rates for cardiac performance measures among
utpatients with CAD, heart failure, and atrial fibrillation vary
ubstantially, ranging from 13% to 97%. These results high-
ight important gaps in the quality of outpatient cardiac care
nd provide a valuable benchmark for future improvement.
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APPENDIX
or the NCDR PINNACLE Registry Data Collection Form v1.0,
lease see the online version of this article.
